Overview

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
Phase:
Phase 1
Details
Lead Sponsor:
Enanta Pharmaceuticals